One, were just at the very beginning of this conversation around peptides
And its easy when youre not that hungry
It does mean that buyers who start a compounded GLP-1 program in mid-2026 should be aware of how quickly the regulatory picture may shift, and should discuss continuity of care planning with their assigned clinical provider before committing to a multi-month program
Think about the long-term financial costs of obesity-related conditions: hypertension, high cholesterol, sleep apnea, and especially type 2 diabetes
Am J Physiol Renal Physiol 301(2):F355F363 Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
We have listed studies below that begin to answer this question